Sonoma Pharmaceuticals files amended 8-K with updated investor presentation; no material new information

Sonoma Pharmaceuticals, Inc.

Amended filing corrects item number from original 8-K dated October 11, 2023.
Investor presentation (October 2023) describes stabilized hypochlorous acid products for dermatology, wound care, etc.
Products are sold directly or via partners in 55 countries; company actively seeks distribution partners.
Presentation contains no financial results, guidance, or material operational updates.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.